C4 Therapeutics Inc Dossier - Source-backed chat

C4 Therapeutics Inc

CCCCNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)2.29

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $3.14Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $386.3M

Enterprise Value $367.7M

Shares Outstanding 140.4M diluted

Next Earnings Date9 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

C4 Therapeutics is a high-potential, clinical-stage biopharmaceutical company pioneering targeted protein degradation (TPD) therapies. The company's proprietary TORPEDO platform has successfully generated a robust pipeline of molecular glues (MonoDACs) and heterobifunctional degraders (BiDACs). The lead candidate, cemsidomide (CFT7455), has demonstrated class-leading anti-myeloma activity and a highly differentiated safety profile in heavily pretreated patients. Backed by a strong cash runway extending to the end of 2028—bolstered by high-value strategic collaborations with Roche, Biogen, and Merck KGaA—C4 Therapeutics is well-positioned to achieve critical clinical inflection points over the next 12 to 24 months.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets6 analysts · as of 18 Aug 2026

Low · most bearish analyst$7.00

Mean target$13.33

High · most bullish analyst$30.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$6.00

Clinical trials for cemsidomide face delays or safety concerns, such as severe neutropenic complications, leading to clinical holds or a compromised product profile. High cash burn in Phase 2 development exhausts the cash runway faster than anticipated, forcing highly dilutive equity raises in a challenging biotech market. Strategic partners scale back collaborations, limiting non-dilutive funding.

Base CaseCentral scenario

$12.17

Cemsidomide successfully advances through the Phase 2 MOMENTUM trial with solid efficacy (ORR ~35-40%) and manageable safety, keeping it on track for a late-line multiple myeloma market entry by 2028. Strategic partnerships continue to offset R&D burn, and the company maintains its cash runway into 2028. Valuation aligns with consensus expectations as clinical milestones are systematically de-risked.

Bull CaseUpside scenario

$30.00

Cemsidomide demonstrates superior efficacy (ORR > 50% at optimal doses) and a best-in-class safety profile in the Phase 2 MOMENTUM trial, leading to accelerated FDA approval by 2028. The combination trial with Pfizer's elranatamab unlocks multi-billion dollar market opportunities in earlier lines of multiple myeloma. Additionally, the expanded Roche DAC collaboration yields multiple high-value development candidates, triggering substantial milestone payments and establishing C4 as the premier partner in the emerging degrader-antibody conjugate modality.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated clinical profile of lead asset cemsidomide (CFT7455), showing strong efficacy and lower rates of dose reductions (6%) and G-CSF use (36%) compared to competitors.
Robust cash position of $268.3 million as of Q1 2026, providing a runway to the end of 2028 and minimizing near-term dilution risk.
High-value strategic partnerships with global pharma leaders (Roche, Biogen, Merck KGaA) validating the TORPEDO platform and providing non-dilutive milestone inflows.

Key Investment Risks

High clinical and regulatory risks inherent to early-stage oncology drug development, with no guaranteed commercialization path.
Intense competition in the targeted protein degradation (TPD) space from well-capitalized peers like Arvinas, Kymera, and Nurix.
Dependence on clinical trial timelines and patient enrollment rates, which are subject to unexpected delays.

Thesis Invalidation Triggers

Failure of cemsidomide to meet primary efficacy or safety endpoints in the Phase 2 MOMENTUM trial.
Imposition of a clinical hold by the FDA on any of the company's active clinical programs.
Termination of major strategic collaborations, particularly the Roche DAC partnership, which would severely impact the cash runway and platform validation.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.